Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 285
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | ||
| NCT02070744 | Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion | ||
| NCT06154447 | Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis | ||
| NCT01931839 | A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis | ||
| NCT00958152 | Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects | ||
| NCT03163511 | A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness | ||
| NCT02516410 | A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation | ||
| NCT00509210 | Study of Telaprevir in Subjects With Hepatic Impairment | ||
| NCT01052194 | A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis | ||
| NCT04537793 | Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years | ||
| NCT04618185 | Gut Imaging for Function & Transit in CF - GIFT-CF 3 | ||
| NCT05541471 | A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin | ||
| NCT02953314 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) | ||
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | ||
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ||
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | ||
| NCT03085485 | The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor | ||
| NCT00205465 | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 | ||
| NCT00591214 | Safety and PK Study of MP-424 to Treat Chronic Hepatitis C | ||
| NCT03125395 | A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | ||
| NCT07283770 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants | ||
| NCT00966602 | Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects | ||
| NCT03764072 | A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | ||
| NCT05865171 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment | ||
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | ||
| NCT04923464 | A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis | ||
| NCT03655678 | A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | ||
| NCT02544451 | Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor | ||
| NCT03859531 | Gastrointestinal Study at Orkambi Therapy in CF Patients | ||
| NCT05560464 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment | ||
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | ||
| NCT01910415 | Phase 1, QT/QTC Interval Study in Healthy Subjects | ||
| NCT05153317 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older | ||
| NCT01707290 | Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation | ||
| NCT00789126 | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects | ||
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | ||
| NCT04977336 | A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | ||
| NCT07584434 | A Phase 1, First-in-human Study of VX-433 | ||
| NCT02392234 | A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation | ||
| NCT06420765 | A Microneurography Study of NaV1.8 Inhibition in Healthy Adults | ||
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | ||
| NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists | ||
| NCT01275599 | Drug-Drug Interaction Study Between Telaprevir and Buprenorphine | ||
| NCT01701063 | An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus | ||
| NCT03525574 | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | ||
| NCT00372385 | Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C | ||
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT01381289 | VX-770 Expanded Access Program | ||
| NCT03525444 | A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | ||
| NCT00758043 | A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response |
